Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac® to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)

NCT03393754 is registered in ClinicalTrials.gov with VBI Vaccines Inc. as lead sponsor.

NCT NCT03393754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03393754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac® to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Lead sponsor
VBI Vaccines Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 13, 2017
Completion date
April 8, 2019
Enrollment
1,607 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b vaccines